Acknowledgement
This article is a condensed form of the first author's doctoral thesis.
References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249. https://doi.org/10.3322/caac.21660
- National Cancer Center. Annual report of cancer statistics in Korea, 2019 [Internet]. Goyang: National Cancer Center; [cited 2023 May 22]. Available from: https://www.ncc.re.kr/cancerStatsView.ncc?bbsnum=598&searchKey=total&searchValue=&pageNum=1
- Union for International Cancer Control (UICC). Global cancer data: GLOBOCAN 2018 [Internet]. Geneva: UICC; [cited 2023 May 22]. Available from: https://www.uicc.org/news/global-cancer-data-globocan-2018
- International Agency for Research on Cancer (IARC). Lung Cancer Awareness Month 2022 [Internet]. Lyon: IARC; [cited 2023 May 22]. Available from: https://www.iarc.who.int/news-events/lung-cancer-awareness-month-2022/
- Toufektchan E, Toledo F. The guardian of the genome revisited: p53 downregulates genes required for telomere maintenance, DNA repair, and centromere structure. Cancers (Basel). 2018;10:135. https://doi.org/10.3390/cancers10050135
- Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol. 2018;15:13-30. https://doi.org/10.1038/nrclinonc.2017.151
- Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol. 2011;2011:583929. https://doi.org/10.1155/2011/583929
- Hecht SS. Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol. 2008;21:160-171. https://doi.org/10.1021/tx7002068
- Bennett WP, Alavanja MC, Blomeke B, Vahakangas KH, Castren K, Welsh JA, et al. Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J Natl Cancer Inst. 1999;91:2009-2014. https://doi.org/10.1093/jnci/91.23.2009
- Hainaut P, Pfeifer GP. Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis. 2001;22:367-374. https://doi.org/10.1093/carcin/22.3.367
- Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 2018;25:154-160. https://doi.org/10.1038/cdd.2017.180
- Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21:7435-7451. https://doi.org/10.1038/sj.onc.1205803
- Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299-311. https://doi.org/10.1016/S0140-6736(16)30958-8
- Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4:36-54. https://doi.org/10.3978/j.issn.2218-6751.2014.05.01
- Al-Ahmadi A, Ardeshir-Larijani F, Fu P, Cao S, Lipka MB, Dowlati A, et al. Next generation sequencing of advanced non-small cell lung cancer: utilization based on race and impact on survival. Clin Lung Cancer. 2021;22:16-22.e1. https://doi.org/10.1016/j.cllc.2020.08.004
- Baek JH, Cho KB. Lung adenocarcinoma gene mutation in Koreans: detection using next generation sequence analysis technique and analysis of concordance with existing genetic test methods. Korean J Clin Lab Sci. 2023;55:16-28. https://doi.org/10.15324/kjcls.2023.55.1.16
- Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543-550. https://doi.org/10.1038/nature13385 Erratum in: Nature. 2014; 514:262. Erratum in: Nature. 2018;559:E12.
- Jiang R, Zhang B, Teng X, Hu P, Xu S, Zheng Z. Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients. Sci Rep. 2020;10:2070. https://doi.org/10.1038/s41598-020-58819-5
- Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 2009;4:22-29. https://doi.org/10.1097/JTO.0b013e3181914111
- Kenmotsu H, Koh Y, Serizawa M, Isaka M, Maniwa T, Murakami H, et al. Abstract 1537: prospective mutational characterization of Japanese patients with non-small cell lung cancer by next-generation sequencing. Cancer Res. 2014;74(Suppl 19):1537. https://doi.org/10.1158/1538-7445.AM2014-1537
- Chun YJ, Choi JW, Hong MH, Jung D, Son H, Cho EK, et al. Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. PLoS One. 2019;14:e0224379. https://doi.org/10.1371/journal.pone.0224379
- Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9:154-162. https://doi.org/10.1097/JTO.0000000000000033
- Suda K, Onozato R, Yatabe Y, Mitsudomi T. EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol. 2009;4:1-4. https://doi.org/10.1097/JTO.0b013e3181913c9f
- Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009;6:201-205. https://doi.org/10.1513/pats.200809-107LC
- Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3:1221-1224. https://doi.org/10.4161/cc.3.10.1164
- Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A. 2005;102:802-807. https://doi.org/10.1073/pnas.0408864102
- Tam KW, Zhang W, Soh J, Stastny V, Chen M, Sun H, et al. CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer. J Thorac Oncol. 2013;8:1378-1388. https://doi.org/10.1097/JTO.0b013e3182a46c0c
- Larsen S, Yokochi T, Isogai E, Nakamura Y, Ozaki T, Nakagawara A. LMO3 interacts with p53 and inhibits its transcriptional activity. Biochem Biophys Res Commun. 2010;392:252-257. https://doi.org/10.1016/j.bbrc.2009.12.010
- Levine AJ, Ting DT, Greenbaum BD. P53 and the defenses against genome instability caused by transposons and repetitive elements. Bioessays. 2016;38:508-513. https://doi.org/10.1002/bies.201600031
- Wylie A, Jones AE, D'Brot A, Lu WJ, Kurtz P, Moran JV, et al. p53 genes function to restrain mobile elements. Genes Dev. 2016;30:64-77. https://doi.org/10.1101/gad.266098.115
- Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51(23 Pt 1):6304-6311.
- Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170:1062-1078. https://doi.org/10.1016/j.cell.2017.08.028
- Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M, et al. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ. 2012;19:1992-2002. https://doi.org/10.1038/cdd.2012.89
- Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092-1100. https://doi.org/10.1128/MCB.19.2.1092
- Boltze C, Roessner A, Landt O, Szibor R, Peters B, Schneider-Stock R. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol. 2002;21:1151-1154. https://doi.org/10.3892/ijo.21.5.1151
- Zhang C, Liu J, Xu D, Zhang T, Hu W, Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 2020;12:674-687. https://doi.org/10.1093/jmcb/mjaa040
- Alvarado-Ortiz E, de la Cruz-Lopez KG, Becerril-Rico J, Sarabia-Sanchez MA, Ortiz-Sanchez E, Garcia-Carranca A. Mutant p53 gain-of-function: role in cancer development, progression, and therapeutic approaches. Front Cell Dev Biol. 2021;8:607670. https://doi.org/10.3389/fcell.2020.607670
- Piao JM, Kim HN, Song HR, Kweon SS, Choi JS, Yun WJ, et al. p53 codon 72 polymorphism and the risk of lung cancer in a Korean population. Lung Cancer. 2011;73:264-267. https://doi.org/10.1016/j.lungcan.2010.12.017
- De Souza C, Madden J, Koestler DC, Minn D, Montoya DJ, Minn K, et al. Effect of the p53 P72R polymorphism on mutant TP53 allele selection in human cancer. J Natl Cancer Inst. 2021;113:1246-1257. https://doi.org/10.1093/jnci/djab019
- Risques RA, Kennedy SR. Aging and the rise of somatic cancer-associated mutations in normal tissues. PLoS Genet. 2018;14:e1007108. https://doi.org/10.1371/journal.pgen.1007108